Short answer
CorMedix Inc. (CRMD) filed an 8-K current report with the SEC on November 2, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). CorMedix announced its cash position for the quarter ended September 30, 2026.
CorMedix Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- CorMedix announced its cash position for the quarter ended September 30, 2026
- Cash-position details and management commentary are contained in Exhibit 99.1
- Liquidity update is material for funding ongoing operations and commercialization activities
Item 7.01 · Regulation FD Disclosure
- Business update and cash position announcement for quarter ended September 30, 2026
- Exhibit 99.1 contains operating details and liquidity information relevant to CorMedix’s near-term outlook
- 2027 DefenCath TDAPA Add-on estimates depend on CMS methodology, utilization, pricing and reimbursement assumptions
- Dialysis-facility reimbursement increases may not translate into higher CorMedix pricing, utilization or revenue
Item EX-99.1 · Exhibit EX-99.1
- Cash and equivalents approximately $355 million as of September 30, 2026, supporting commercial expansion and near-term liquidity
- 2026 revenue guidance reaffirmed at $325 million to $345 million, reducing risk of an in-quarter outlook cut
- CMS set DefenCath’s Q1 2027 post-TDAPA Add-on at $8.32 per dialysis session, versus $2.37 in Q3-Q4 2026
- Management expects 2027 Add-on rates above $2.37 every quarter, with the annual average exceeding 2x the current rate
- Q2 2027 Add-on decline expected before recovery in Q3 and/or Q4, creating quarterly reimbursement volatility for investors
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CorMedix Inc. 8-K filings
Get the next CRMD 8-K as it lands
Follow CRMD for push alerts, or ask the research agent what this filing means.